Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cytek Biosciences Inc (NQ: CTKB )

9.190 +0.280 (+3.14%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,108,997
Open 9.080
Bid (Size) 8.560 (1)
Ask (Size) 9.500 (200)
Prev. Close 8.910
Today's Range 8.950 - 9.390
52wk Range 7.380 - 16.05
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cytek® Biosciences Introduces New 20-Color AML Panel
Optimized for Cytek Cell Analysis Systems; Single-Tube Panel Accelerates Acute Myeloid Leukemia Research and MRD Detection 
From Cytek Biosciences, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga

Performance

YTD
-9.19%
-9.19%
1 Month
-4.67%
-4.67%
3 Month
-9.19%
-9.19%
6 Month
-39.93%
-39.93%
1 Year
-15.53%
-15.53%

More News

Read More
Cytek Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results
From Cytek Biosciences, Inc.
Via Globe NewsWire
Sale of Flow Cytometry and Imaging Business From DiaSorin to Cytek® Biosciences Completed
From Cytek Biosciences, Inc.
Via Globe NewsWire
Cytek Biosciences Acquires Flow Cytometry & Imaging Business From DiaSorin
Via Benzinga
Why Top Ships Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Cytek® Biosciences to Acquire Flow Cytometry and Imaging Business from DiaSorin
From Cytek Biosciences, Inc.
Via Globe NewsWire
Cytek Biosciences Earnings Perspective: Return On Capital Employed
Via Benzinga
Recap: Cytek Biosciences Q2 Earnings
Via Benzinga
Earnings Preview: Cytek Biosciences
Via Benzinga
Cytek Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023
From Cytek Biosciences, Inc.
Via Globe NewsWire
Cytek® Biosciences Partners with Bio-Rad to Expand Reagent Portfolios
From Cytek Biosciences, Inc.
Via Globe NewsWire
Cytek Biosciences to Participate in Upcoming Investor Conferences
From Cytek Biosciences, Inc.
Via Globe NewsWire
Oak Street Health, PriceSmart And Some Other Big Stocks Moving Higher In Tuesday's Pre-Market Session
Via Benzinga
5 Most Cheapest Stocks In The Healthcare Sector: Bio-Techne, Mirati Therapeutics And More
Via Benzinga
Cytek Biosciences to Participate in the Piper Sandler Healthcare Conference
From Cytek Biosciences, Inc.
Via Globe NewsWire
Cytek® Biosciences Introduces Cytek Cloud
From Cytek Biosciences, Inc.
Via Globe NewsWire
Cytek Biosciences Reports Third Quarter 2022 Financial Results
From Cytek Biosciences, Inc.
Via Globe NewsWire
Earnings Outlook For Cytek Biosciences
Via Benzinga
Cytek® Biosciences Names Chris Williams Chief Operating Officer
From Cytek Biosciences, Inc.
Via Globe NewsWire
Cytek Biosciences to Report Third Quarter 2022 Financial Results on November 9, 2022
From Cytek Biosciences, Inc.
Via Globe NewsWire
Cytek to Participate in the 31st Annual Credit Suisse Healthcare Conference
From Cytek Biosciences, Inc.
Via Globe NewsWire
Pinterest, Perion Network And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
Via Benzinga
Piper Sandler Maintains Overweight Rating for Cytek Biosciences: Here's What You Need To Know
Via Benzinga
Analyst Ratings for Cytek Biosciences
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.